Drug combination therapy increases successful drug repositioning.

Repositioning of approved drugs has recently gained new momentum for rapid identification and development of new therapeutics for diseases that lack effective drug treatment. Reported repurposing screens have increased dramatically in number in the past five years. However, many newly identified compounds have low potency; this limits their immediate clinical applications because the known, tolerated plasma drug concentrations are lower than the required therapeutic drug concentrations. Drug combinations of two or more compounds with different mechanisms of action are an alternative approach to increase the success rate of drug repositioning.

[1]  Stephen T. C. Wong,et al.  Toward better drug repositioning: prioritizing and integrating existing methods into efficient pipelines. , 2014, Drug discovery today.

[2]  M. MacDonald,et al.  Reversal of a full-length mutant huntingtin neuronal cell phenotype by chemical inhibitors of polyglutamine-mediated aggregation , 2005, BMC Neuroscience.

[3]  Péter Csermely,et al.  The efficiency of multi-target drugs: the network approach might help drug design. , 2004, Trends in pharmacological sciences.

[4]  Jun O. Liu,et al.  A clinical drug library screen identifies astemizole as an antimalarial agent , 2006, Nature chemical biology.

[5]  I. Chumakov,et al.  An exploratory randomised double-blind and placebo-controlled phase 2 study of a combination of baclofen, naltrexone and sorbitol (PXT3003) in patients with Charcot-Marie-Tooth disease type 1A , 2014, Orphanet Journal of Rare Diseases.

[6]  C. Lindsley.  2014 prescription medications in the United States: tremendous growth, specialty/orphan drug expansion, and dispensed prescriptions continue to increase. , 2015, ACS chemical neuroscience.

[7]  Paul A Clemons,et al.  The Connectivity Map: Using Gene-Expression Signatures to Connect Small Molecules, Genes, and Disease , 2006, Science.

[8]  A. Barabasi,et al.  Network medicine : a network-based approach to human disease , 2010 .

[9]  Robert H. Brown,et al.  Intrinsic membrane hyperexcitability of amyotrophic lateral sclerosis patient-derived motor neurons. , 2014, Cell reports.

[10]  May Ho,et al.  Plasmodium falciparum genome-wide scans for positive selection, recombination hot spots and resistance to antimalarial drugs , 2010, Nature Genetics.

[11]  Shinichiro Okamoto,et al.  Successful treatment of adult onset Langerhans cell histiocytosis with multi-drug combination therapy. , 2011, Internal medicine.

[12]  Chih-Ming Ho,et al.  Optimization of drug combinations using Feedback System Control , 2016, Nature Protocols.

[13]  Gisbert Schneider,et al.  Multidimensional de novo design reveals 5-HT2B receptor-selective ligands. , 2015, Angewandte Chemie.

[14]  D. Kwiatkowski,et al.  Spread of artemisinin resistance in Plasmodium falciparum malaria. , 2014, The New England journal of medicine.

[15]  Luis G Valerio,et al.  A novel QSAR model of Salmonella mutagenicity and its application in the safety assessment of drug impurities. , 2013, Toxicology and applied pharmacology.

[16]  Clive N. Svendsen,et al.  Human stem cells and drug screening: opportunities and challenges , 2010, Nature Reviews Drug Discovery.

[17]  M. Kollef,et al.  Multi-drug resistance, inappropriate initial antibiotic therapy and mortality in Gram-negative severe sepsis and septic shock: a retrospective cohort study , 2014, Critical Care.

[18]  Natsuyo Aoyama,et al.  Phenotypic Screening with Human iPS Cell–Derived Cardiomyocytes , 2013, Journal of biomolecular screening.

[19]  Kewei Chen,et al.  A phase Ib multiple ascending dose study of the safety, tolerability, and central nervous system availability of AZD0530 (saracatinib) in Alzheimer’s disease , 2015, Alzheimer's Research & Therapy.

[20]  Jun O. Liu,et al.  Phase 2 Study of Pemetrexed and Itraconazole as Second-Line Therapy for Metastatic Nonsquamous Non–Small-Cell Lung Cancer , 2013, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[21]  Petra Schneider,et al.  Multi-objective molecular de novo design by adaptive fragment prioritization. , 2014, Angewandte Chemie.

[22]  Xu Han,et al.  Literature Based Drug Interaction Prediction with Clinical Assessment Using Electronic Medical Records: Novel Myopathy Associated Drug Interactions , 2012, PLoS Comput. Biol..

[23]  M. Markowitz,et al.  A Randomized Open-Label Study of 3- Versus 5-Drug Combination Antiretroviral Therapy in Newly HIV-1–Infected Individuals , 2014, Journal of acquired immune deficiency syndromes.

[24]  M. Schuemie,et al.  The role of electronic healthcare record databases in paediatric drug safety surveillance: a retrospective cohort study. , 2015, British journal of clinical pharmacology.

[25]  K. Shokat,et al.  Targeting the cancer kinome through polypharmacology , 2010, Nature Reviews Cancer.

[26]  David S. Goodsell,et al.  The RCSB Protein Data Bank: views of structural biology for basic and applied research and education , 2014, Nucleic Acids Res..

[27]  Peter C Austin,et al.  Selective serotonin reuptake inhibitors and breast cancer mortality in women receiving tamoxifen: a population based cohort study , 2010, BMJ : British Medical Journal.

[28]  M L Bolognesi,et al.  Polypharmacology in a single drug: multitarget drugs. , 2013, Current medicinal chemistry.

[29]  M. Reich,et al.  Essential medicines are still essential , 2015, The Lancet.

[30]  C. Austin,et al.  Identification of Therapeutic Candidates for Chronic Lymphocytic Leukemia from a Library of Approved Drugs , 2013, PloS one.

[31]  D. Swinney,et al.  How were new medicines discovered? , 2011, Nature Reviews Drug Discovery.

[32]  F. Buckner,et al.  Synergy Testing of FDA-Approved Drugs Identifies Potent Drug Combinations against Trypanosoma cruzi , 2014, PLoS neglected tropical diseases.

[33]  Paul Shinn,et al.  Identification of 53 compounds that block Ebola virus-like particle entry via a repurposing screen of approved drugs , 2014, Emerging Microbes & Infections.

[34]  Ruili Huang,et al.  The NCGC Pharmaceutical Collection: A Comprehensive Resource of Clinically Approved Drugs Enabling Repurposing and Chemical Genomics , 2011, Science Translational Medicine.

[35]  M. Borad,et al.  Phase I Study of Bosutinib, a Src/Abl Tyrosine Kinase Inhibitor, Administered to Patients with Advanced Solid Tumors , 2011, Clinical Cancer Research.

[36]  R. Minter,et al.  Identification of anti-tumour biologics using primary tumour models, 3-D phenotypic screening and image-based multi-parametric profiling , 2015, Molecular Cancer.

[37]  L. Mucke,et al.  A network dysfunction perspective on neurodegenerative diseases , 2006, Nature.

[38]  Sam Michael,et al.  High-throughput matrix screening identifies synergistic and antagonistic antimalarial drug combinations , 2015, Scientific Reports.

[39]  David A. Flockhart,et al.  CYP2D6 genotype, antidepressant use, and tamoxifen metabolism during adjuvant breast cancer treatment. , 2005, Journal of the National Cancer Institute.

[40]  Rachel M. Webster.  Combination therapies in oncology , 2016, Nature Reviews Drug Discovery.

[41]  L. Peshkin,et al.  Exploiting polypharmacology for drug target deconvolution , 2014, Proceedings of the National Academy of Sciences.

[42]  G. Everson,et al.  Drug–drug interactions during antiviral therapy for chronic hepatitis C , 2013, Nature Reviews Gastroenterology &Hepatology.

[43]  S. Frantz.  The trouble with making combination drugs. , 2006, Nature reviews. Drug discovery.

[44]  J. Walochnik,et al.  Miltefosine and polyhexamethylene biguanide: a new drug combination for the treatment of Acanthamoeba keratitis , 2014, Clinical & experimental ophthalmology.

[45]  Christopher P Austin,et al.  High-Throughput Multiplexed Quantitation of Protein Aggregation and Cytotoxicity in a Huntington’s Disease Model , 2012, Current chemical genomics.

[46]  G. Muirhead,et al.  Sildenafil: an orally active type 5 cyclic GMP-specific phosphodiesterase inhibitor for the treatment of penile erectile dysfunction. , 1996, International journal of impotence research.

[47]  Jun O. Liu,et al.  Inhibition of angiogenesis by the antifungal drug itraconazole. , 2007, ACS chemical biology.

[48]  M. Manns,et al.  Second-wave protease inhibitors: choosing an heir. , 2011, Clinics in liver disease.

[49]  J. Karlowsky,et al.  Ceftazidime-Avibactam: a Novel Cephalosporin/β-lactamase Inhibitor Combination , 2013, Drugs.

[50]  Gang Zhao,et al.  Metformin and temozolomide act synergistically to inhibit growth of glioma cells and glioma stem cells in vitro and in vivo , 2015, Oncotarget.

[51]  Sridhar Ramaswamy,et al.  Patient-derived models of acquired resistance can identify effective drug combinations for cancer , 2014, Science.

[52]  A. Butte,et al.  Relating Chemical Structure to Cellular Response: An Integrative Analysis of Gene Expression, Bioactivity, and Structural Data Across 11,000 Compounds , 2015, CPT: pharmacometrics & systems pharmacology.

[53]  Yi-Cheng Tu,et al.  A novel algorithm for analyzing drug-drug interactions from MEDLINE literature , 2015, Scientific Reports.

[54]  D. Ho,et al.  Time to hit HIV, early and hard. , 1995, The New England journal of medicine.

[55]  Luca Pinzi,et al.  Computational polypharmacology comes of age , 2015, Front. Pharmacol..

[56]  Michael J. Keiser,et al.  Large Scale Prediction and Testing of Drug Activity on Side-Effect Targets , 2012, Nature.

[57]  A 4-drug combination (Viekira Pak) for hepatitis C. , 2015, The Medical letter on drugs and therapeutics.

[58]  Ruili Huang,et al.  Chemical signatures and new drug targets for gametocytocidal drug development , 2014, Scientific Reports.

[59]  J. Hidalgo,et al.  Ceftazidime/avibactam: a novel cephalosporin/nonbeta-lactam beta-lactamase inhibitor for the treatment of complicated urinary tract infections and complicated intra-abdominal infections , 2016, Drug design, development and therapy.

[60]  Christopher P Austin,et al.  δ-Tocopherol Reduces Lipid Accumulation in Niemann-Pick Type C1 and Wolman Cholesterol Storage Disorders* , 2012, The Journal of Biological Chemistry.

[61]  Dan C. Fara,et al.  Lead-like, drug-like or “Pub-like”: how different are they? , 2007, J. Comput. Aided Mol. Des..

[62]  Wei Zheng,et al.  Phenotypic screens as a renewed approach for drug discovery. , 2013, Drug discovery today.

[63]  Mohieddin Jafari,et al.  Updates on drug-target network; facilitating polypharmacology and data integration by growth of DrugBank database , 2015, Briefings Bioinform..

[64]  S. Strittmatter,et al.  Fyn inhibition rescues established memory and synapse loss in Alzheimer mice , 2015, Annals of neurology.

[65]  Xiaohua Ma,et al.  Mechanisms of drug combinations: interaction and network perspectives , 2009, Nature Reviews Drug Discovery.

[66]  Asher Mullard.  2014 FDA drug approvals , 2015, Nature Reviews Drug Discovery.

[67]  George Hripcsak,et al.  Similarity-based modeling in large-scale prediction of drug-drug interactions , 2014, Nature Protocols.